DFM Platform
DFM Funding Monitor

The i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune systembroad

i-THYMUS · Horizon Europe grant · 2023-11-01–2025-10-31

EC contribution

€2,495,511

Total cost

€3,565,016

Beneficiaries

2
About the data

Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2023-ACCELERATOROPEN-01. CORDIS record →

Objective

Each year, >250 babies are born without a thymus. These babies have a life expectancy of 2-3 years. The only cure is transplantation of thymus tissue, but this has a 30% mortality rate and costs almost >€2.5M. We developed i-Thymus, a revolutionary cure based on the patient’s own cells leveraging innovative gene therapy to generate thymus organoids that can be implanted minimally invasively in the patient (Fig. 1). We have already shown this works in functional proof of concept in vivo. With this EIC Accelerator, we will finalise development to enter the clinic for a Phase I/II trial, to enter the EU market with a pharma partner by 2028. After rapid market entry with ODD for complete DiGeorge syndrome, we will leverage this clinical success and our first revenues to develop i-Thymus for unmet needs of hundreds of thousands of other patients, starting with AML patients who have lost thymus function after high-dose chemotherapy for stem cell transplantation.

Beneficiaries (2)

OrganisationCountryRoleEC contributionSME
GENEWITY BV NL coordinator €2,495,511 Yes
Genewity Holding BV NL thirdParty €0 Yes

Get the EU Defence Funding Calendar — free

The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.

We store your email to send the calendar and the weekly DFM Analysis briefing. Nothing else. Unsubscribe anytime.

Or browse all open defence & dual-use calls on the funding calendar →

Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.

DFM Analysis, our free weekly newsletter, tracks the EU defence-funding programmes, calls and decisions behind this page. Subscribe free →